Activation of mTORC1 in collecting ducts causes hyperkalemia

Journal of the American Society of Nephrology

Volumn 25, Issue 3, 2014, Pages 534-545

  Chen, Zhenguo ^a   Dong, Heling ^a   Jia, Chunhong ^a   Song, Qiancheng ^a   Chen, Juan ^a   Zhang, Yue ^a   Lai, Pinglin ^a   Fan, Xiaorong ^a   Zhou, Xuan ^a   Liu, Miao ^a   Lin, Jun ^a   Yang, Cuilan ^a   Li, Ming ^a   Gao, Tianming ^a   Bai, Xiaochun ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALDOSTERONE; AQUAPORIN 2; EPITHELIAL SODIUM CHANNEL; EPITHELIAL SODIUM CHANNEL ALPHA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; POTASSIUM CHANNEL; RAPAMYCIN; RENAL OUTER MEDULLARY POTASSIUM CHANNEL; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DAMAGE; CELL DEDIFFERENTIATION; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; EPITHELIAL MESENCHYMAL TRANSITION; HOMEOSTASIS; HYPERALDOSTERONISM; HYPERKALEMIA; KIDNEY COLLECTING TUBULE; METABOLIC ACIDOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOHYPOALDOSTERONISM;

ANIMALS; CELL DEDIFFERENTIATION; ENDOPLASMIC RETICULUM STRESS; EPITHELIAL SODIUM CHANNELS; FEMALE; HOMEOSTASIS; HYPERKALEMIA; IMMEDIATE-EARLY PROTEINS; KIDNEY TUBULES, COLLECTING; MALE; MICE; MICE, KNOCKOUT; MULTIPROTEIN COMPLEXES; PHENOTYPE; POTASSIUM; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PROTEIN-SERINE-THREONINE KINASES; SIROLIMUS; SODIUM-POTASSIUM-EXCHANGING ATPASE; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84896854048     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013030225     Document Type: Article

References (52)

1. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl JMed 351: 543-551, 2004 (Pubitemid 39025171)
2. Nyirenda MJ, Tang JI, Padfield PL, Seckl JR: Hyperkalaemia. BMJ 339: 1019-1024, 2009
3. Hollander-Rodriguez JC, Calvert JF Jr: Hyperkalemia. Am Fam Physician 73: 283-290, 2006
4. Lehnhardt A, Kemper MJ: Pathogenesis, diagnosis and management of hyperkalemia. Pediatr Nephrol 26: 377-384, 2011
5. Palmer LG, Frindt G: Aldosterone and potassium secretion by the cortical collecting duct. Kidney Int 57: 1324-1328, 2000 (Pubitemid 30207886)
6. Gennari FJ, Segal AS: Hyperkalemia: An adaptive response in chronic renal insufficiency. Kidney Int 62: 1-9, 2002
7. Wang W: Renal potassium channels: Recent developments. Curr Opin Nephrol Hypertens 13: 549-555, 2004
8. Liu Z, Wang HR, Huang CL: Regulation of ROMK channel and K+ homeostasis by kidney-specific WNK1 kinase. J Biol Chem 284: 12198-12206, 2009
9. Karet FE: Mechanisms in hyperkalemic renal tubular acidosis. J Am Soc Nephrol 20: 251-254, 2009
10. Stokes JB: Sodium and potassium transport by the collecting duct. Kidney Int 38: 679-686, 1990
11. Eaton DC, Malik B, Saxena NC, Al-Khalili OK, Yue G: Mechanisms of aldosterone' s action on epithelial Na + transport. J Membr Biol 184: 313-319, 2001 (Pubitemid 34033087)
12. Muto S: Potassium transport in the mammalian collecting duct. Physiol Rev 81: 85-116, 2001
13. Meneton P, Loffing J, Warnock DG: Sodium and potassiumhandling by the aldosterone-sensitive distal nephron: The pivotal role of the distal and connecting tubule. Am J Physiol Renal Physiol 287: F593-F601, 2004 (Pubitemid 39280492)
14. Soundararajan R, Lu M, Pearce D: Organization of the ENaC-regulatory machinery. Crit Rev Biochem Mol Biol 47: 349-359, 2012
15. Palmer BF: Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 351: 585-592, 2004
16. Lang F, Böhmer C, Palmada M, Seebohm G, Strutz-Seebohm N, Vallon V: (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms. Physiol Rev 86: 1151-1178, 2006 (Pubitemid 44521650)
17. Zoncu R, Efeyan A, Sabatini DM:mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35, 2011
18. Laplante M, Sabatini DM: mTOR signaling at a glance. J Cell Sci 122: 3589-3594, 2009
19. Bai X, Jiang Y: Key factors in mTOR regulation. Cell Mol Life Sci 67: 239-253, 2010
20. Ma XM, Blenis J: Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10: 307-318, 2009
21. Laplante M, Sabatini DM: mTOR signaling in growth control and disease. Cell 149: 274-293, 2012
22. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, Sabatini DM: The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320: 1496-1501, 2008
23. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO, Guan KL: TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126: 955-968, 2006
24. Inoki K, Corradetti MN, Guan KL: Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37: 19-24, 2005 (Pubitemid 40070934)
25. Lieberthal W, Levine JS: The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 20: 2493-2502, 2009
26. Zhou J, Brugarolas J, Parada LF: Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1. Hum Mol Genet 18: 4428-4441, 2009
27. Wu MJ, Wen MC, Chiu YT, Chiou YY, Shu KH, Tang MJ: Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 69: 2029-2036, 2006
28. Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, Lieberthal W: Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 16: 2063-2072, 2005 (Pubitemid 41716437)
29. Gödel M, Hartleben B, Herbach N, Liu S, Zschiedrich S, Lu S, Debreczeni-Mór A, Lindenmeyer MT, Rastaldi MP, Hartleben G, Wiech T, Fornoni A, Nelson RG, Kretzler M, Wanke R, Pavenstädt H, Kerjaschki D, Cohen CD, Hall MN, Rüegg MA, Inoki K, Walz G, Huber TB: Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 121: 2197-2209, 2011
30. Cinà DP, Onay T, Paltoo A, Li C, Maezawa Y, De Arteaga J, Jurisicova A, Quaggin SE: Inhibition of MTOR disrupts autophagic flux in podocytes. J Am Soc Nephrol 23: 412-420, 2012
31. Inoki K, Mori H, Wang J, Suzuki T, Hong S, Yoshida S, Blattner SM, Ikenoue T, Rüegg MA, Hall MN, Kwiatkowski DJ, Rastaldi MP, Huber TB, Kretzler M, Holzman LB, Wiggins RC, Guan KL: mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 121: 2181-2196, 2011
32. Murthy V, Haddad LA, Smith N, Pinney D, Tyszkowski R, Brown D, Ramesh V: Similarities and differences in the subcellular localization of hamartin and tuberin in the kidney. Am J Physiol Renal Physiol 278: F737-F746, 2000 (Pubitemid 30351075)
33. Vallon V, Lang F: New insights into the role of serum- and glucocorticoid-inducible kinase SGK1 in the regulation of renal function and blood pressure. Curr Opin Nephrol Hypertens 14: 59-66, 2005 (Pubitemid 40110701)
34. Kwiatkowski DJ: Tuberous sclerosis: From tubers to mTOR. Ann Hum Genet 67: 87-96, 2003
35. Furgeson SB, Linas S: Mechanisms of type I and type II pseudohypoaldosteronism. J Am Soc Nephrol 21: 1842-1845, 2010
36. Yang SS, Morimoto T, Rai T, Chiga M, Sohara E, Ohno M, Uchida K, Lin SH, Moriguchi T, Shibuya H, Kondo Y, Sasaki S, Uchida S: Molecular pathogenesis of pseudohypoaldosteronism type II: Generation and analysis of aWnk4(D561A/+) knockinmousemodel. Cell Metab 5: 331-344, 2007 (Pubitemid 46679517)
37. Pinder SE, Reis-Filho JS: Non-operative breast pathology: Columnar cell lesions. J Clin Pathol 60: 1307-1312, 2007 (Pubitemid 350247245)
38. Dessauvagie BF, Zhao W, Heel-Miller KA, Harvey J, Bentel JM: Characterization of columnar cell lesions of the breast: immunophenotypic analysis of columnar alteration of lobules with prominent apical snouts and secretions. Hum Pathol 38: 284-292, 2007 (Pubitemid 46096552)
39. Ai D, Baez JM, Jiang H, Conlon DM, Hernandez-Ono A, Frank-Kamenetsky M, Milstein S, Fitzgerald K, Murphy AJ, Woo CW, Strong A, Ginsberg HN, Tabas I, Rader DJ, Tall AR: Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice. J Clin Invest 122: 1677-1687, 2012
40. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, Görgün CZ, Hotamisligil GS: Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313: 1137-1140, 2006
41. Pao AC: SGK regulation of renal sodium transport. Curr Opin Nephrol Hypertens 21: 534-540, 2012
42. Lang F, Artunc F, Vallon V: The physiological impact of the serum and glucocorticoid-inducible kinase SGK1. Curr Opin Nephrol Hypertens 18: 439-448, 2009
43. Menon S, Yecies JL, Zhang HH, Howell JJ, Nicholatos J, Harputlugil E, Bronson RT, Kwiatkowski DJ, Manning BD: Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci Signal 5: 1-11, 2012
44. Faresse N, Lagnaz D, Debonneville A, Ismailji A, Maillard M, Fejes-Toth G, Náray-Fejes-Tóth A, Staub O: Inducible kidney-specific Sgk1 knockout mice show a salt-losing phenotype. Am J Physiol Renal Physiol 302: F977-F985, 2012
45. Arroyo JP, Lagnaz D, Ronzaud C, Vázquez N, Ko BS, Moddes L, Ruffieux-Daidié D, Hausel P, Koesters R, Yang B, Stokes JB, Hoover RS, Gamba G, Staub O: Nedd4-2 modulates renal Na+-Cl- cotransporter via the aldosterone-SGK1-Nedd4-2 pathway. J Am Soc Nephrol 22: 1707-1719, 2011
46. Thomas SV, Kathpalia PP, Rajagopal M, Charlton C, Zhang J, Eaton DC, Helms MN, Pao AC: Epithelial sodium channel regulation by cell surface-associated serum- and glucocorticoid-regulated kinase 1. J Biol Chem 286: 32074-32085, 2011
47. Jones KT, Greer ER, Pearce D, Ashrafi K: Rictor/TORC2 regulates Caenorhabditis elegans fat storage, body size, and development through sgk-1. PLoS Biol 7: e60, 2009
48. Toker A: mTOR and Akt signaling in cancer: SGK cycles in. Mol Cell 31: 6-8, 2008
49. Batlle DC, Arruda JA, Kurtzman NA: Hyperkalemic distal renal tubular acidosis associated with obstructive uropathy. NEngl JMed 304: 373-380, 1981 (Pubitemid 11167435)
50. Fenic I, Sonnack V, Failing K, Bergmann M, Steger K: In vivo effects of histone-deacetylase inhibitor trichostatin-A on murine spermatogenesis. J Androl 25: 811-818, 2004 (Pubitemid 39096318)
51. Tomita K, Nonoguchi H, Marumo F: Effects of endothelin on peptide-dependent cyclic adenosine monophosphate accumulation along the nephron segments of the rat. J Clin Invest 85: 2014-2018, 1990 (Pubitemid 20192981)
52. Marin-Castaño ME, Schanstra JP, Praddaude F, Pesquero JB, Ader JL, Girolami JP, Bascands JL: Differential induction of functional B1-bradykinin receptors along the rat nephron in endotoxin induced inflammation. Kidney Int 54: 1888-1898, 1998 (Pubitemid 28533617)